Find More Contacts for Effector Therapeutics
Protected Content
CBO
Executive Management
3 emails found 1 phone number found
View contacts for Effector Therapeutics to access new leads and connect with decision-makers.
View All Contacts
  • Contact Email info@effector.com
  • Phone Number 8589258215

eFFECTOR is a clinical stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs). eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The eIF4F

complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select messenger RNA into proteins that are frequent culprits in key disease driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK 1/2 inhibitor. KICKSTART, a randomized, double-blind, placebo controlled Phase 2b trial of tomivorsertib in NSCLC in combination with pembrolizumab is currently open for enrollment. Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently in the dose-escalation portion of a Phase 1/2 trial, with Phase 2a expansion cohorts expected to initiate in the second half of 2021. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

Lists Featuring This Company

Medical Public Companies With Fewer Than 50 Employees
500 Number of Organizations • $21.1B Total Funding Amount • 1,061 Number of Investors
Western US Companies With More Than $1M in Revenue (Top 10K)
9,942 Number of Organizations • $1.6T Total Funding Amount • 83,676 Number of Investors
Health Care Companies With Less Than $500M in Revenue (Top 10K)
9,983 Number of Organizations • $660.8B Total Funding Amount • 55,740 Number of Investors
Greater San Diego Area Companies With More Than $1M in Revenue (Top 10K)
9,952 Number of Organizations • $95.5B Total Funding Amount • 4,499 Number of Investors

Frequently Asked Questions

Where is Effector Therapeutics's headquarters? Effector Therapeutics is located in San Diego, California, United States.Who invested in Effector Therapeutics? Effector Therapeutics has 15 investors including The Column Group and Alexandria Venture Investments.How much funding has Effector Therapeutics raised to date? Effector Therapeutics has raised .When was the last funding round for Effector Therapeutics? Effector Therapeutics closed its last funding round on Jan 25, 2024 from a Post-IPO Equity round.Who are Effector Therapeutics's competitors? Alternatives and possible competitors to Effector Therapeutics may include GalapagosBlueprint Medicines, and Rapt Therapeutics.